Literature DB >> 27348731

Copeptin and Decline in Kidney Function.

Jingyin Yan1, Sankar D Navaneethan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27348731      PMCID： PMC5408578          DOI： 10.1159/000447369

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


× No keyword cloud information.
  10 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort.

Authors:  S Enhörning; L Bankir; N Bouby; J Struck; B Hedblad; M Persson; N G Morgenthaler; P M Nilsson; O Melander
Journal:  Int J Obes (Lond)       Date:  2012-05-22       Impact factor: 5.095

3.  Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Authors:  W E Boertien; I J Riphagen; I Drion; A Alkhalaf; S J L Bakker; K H Groenier; J Struck; P E de Jong; H J G Bilo; N Kleefstra; R T Gansevoort
Journal:  Diabetologia       Date:  2013-04-28       Impact factor: 10.122

4.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.

Authors:  Wiebke Fenske; Christoph Wanner; Bruno Allolio; Christiane Drechsler; Katja Blouin; Jürgen Lilienthal; Vera Krane
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

5.  Copeptin: clinical use of a new biomarker.

Authors:  Nils G Morgenthaler; Joachim Struck; Stefan Jochberger; Martin W Dünser
Journal:  Trends Endocrinol Metab       Date:  2008-03       Impact factor: 12.015

6.  Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population.

Authors:  Irina Tasevska; Sofia Enhörning; Anders Christensson; Margaretha Persson; Peter M Nilsson; Olle Melander
Journal:  Am J Nephrol       Date:  2016-06-28       Impact factor: 3.754

7.  Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Authors:  Tadashi Okada; Toshifumi Sakaguchi; Ikuji Hatamura; Fumie Saji; Shigeo Negi; Haruhisa Otani; Yasuteru Muragaki; Hiroshi Kawachi; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

8.  Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.

Authors:  Esther Meijer; Stephan J L Bakker; Nynke Halbesma; Paul E de Jong; Joachim Struck; Ron T Gansevoort
Journal:  Kidney Int       Date:  2010-01       Impact factor: 10.612

9.  Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.

Authors:  Ronan Roussel; Nadia Matallah; Nadine Bouby; Ray El Boustany; Louis Potier; Frédéric Fumeron; Kamel Mohammedi; Beverley Balkau; Michel Marre; Lise Bankir; Gilberto Velho
Journal:  Am J Nephrol       Date:  2015-09-09       Impact factor: 3.754

10.  Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.

Authors:  Jessica M Sontrop; Shi-Han Huang; Amit X Garg; Louise Moist; Andrew A House; Kerri Gallo; William F Clark
Journal:  BMJ Open       Date:  2015-11-24       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.